What the FDA labels say about taking them together
Orforglipron and ritonavir
Orforglipron's FDA label of July 29, 2026 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name orforglipron. The orforglipron label: “Avoid concomitant use of FOUNDAYO with strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir).”
Check it at the source: the orforglipron FDA label on DailyMed (effective July 29, 2026, Eli Lilly and Company); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).
What does the orforglipron label say about ritonavir?
Orforglipron label, drug interactionsAvoid concomitant use of FOUNDAYO with strong CYP3A4 inhibitors that also inhibit OATP1B (e.g., ritonavir) [see Dosage and Administration ( 2.2 )].
Source: FDA drug label (FOUNDAYO), Eli Lilly and Company, effective July 29, 2026 (SPL set 8ac446c5-feba-474f-a103-23facb9b5c62), via openFDA; the full label on DailyMed
What does the ritonavir label say about orforglipron?
Ritonavir's label (effective July 23, 2026) does not name orforglipron in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Orforglipron | Ritonavir | |
|---|---|---|
| Labeled for | Weight management | HIV |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $20.89 per tablet 0.8 mg tablet | $0.607 per tablet 100 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once